Orphan drugs in Italy: availability and time-to-access at regional level-Reference-Cited by-同舟云学术

Orphan drugs in Italy: availability and time-to-access at regional level

Published:2023-12-28 Issue: Volume:10 Page:89-97
ISSN:2283-5733
Container-title:Global and Regional Health Technology Assessment
language:
Short-container-title:Grhta

Author:

Marino Maria Lucia^ORCID,Alessi Eva,Di Filippo Aurora,Polistena Barbara^ORCID,Macchia Francesco,Spandonaro Federico^ORCID,Trotta Francesco^ORCID

Abstract

Introduction: There are an estimated 26 million rare disease patients in Europe, about 2 million in Italy. Access to orphan drugs has been evaluated nationally and internationally, and delays have been observed due to evaluation of price and therapeutic value. The objectives of this study are: to assess the availability of EMA-authorized orphan drugs at national and regional level; to study time trends and regional variability in consumption and spending, and to estimate the time to access in Italian regions. Methods: We evaluate the availability of EMA authorized orphan drugs in Italy. Based on data from the Traceability of medicines dataflow for period 2016-2021 we evaluate the expenditure, consumption and availability of orphan drugs in each region. To estimate the time to access we consider the days between the end of negotiation procedure and the first purchase by regions. Results: In 2021 in Italy are available 94% of EMA authorized orphan drugs. The expenditure and consumption have grown during the last decade. The availability is higher in bigger regions, that also take care of patients from smaller regions. The pro capite expenditure and consumption in DDD/1,000 ab die is similar in all the geographic area. Time to regional access is on average 123 days, that grows to 224 excluding the orphan drugs dispensed before the end of reimbursement procedure.

Publisher

Aboutscience Srl

Subject

General Medicine

Reference25 articles.

1. European Medicines Agency. Human regulatory. Orphan designation. https://www.ema.europa.eu/en/human-regulatory/overview/orphan-designation-overview (Accessed: July 2023)

2. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32000R0141&from=EN (Accessed July 2023)

3. UNIAMO Federazione Italiana Malattie Rare. Le Malattie rare: cosa sono. https://uniamo.org/malattie-rare-cosa-sono/ (Accessed July 2023)

4. Legge 8 novembre 2012, n. 189. Conversione in legge, con modificazioni, del decreto-legge 13 settembre 2012, n. 158, recante disposizioni urgenti per promuovere lo sviluppo del Paese mediante un piu' alto livello di tutela della salute. (12G0212) (Entrata in vigore del provvedimento: 11/11/2012 pubblicata su GU n.263 del 10-11-2012 - Suppl. Ordinario n. 201) (https://www.gazzettaufficiale.it/eli/id/2012/11/10/012G0212/sg ) (Accessed July 2023)

5. Legge 23 dicembre 1996, n. 648. Conversione in legge del decreto-legge 21 ottobre 1996, n. 536, recante misure per il contenimento della spesa farmaceutica e la rideterminazione del tetto di spesa per l'anno 1996 (pubblicata in GU n.300 del 23-12-1996). https://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario?atto.dataPubblicazioneGazzetta=1996-12-23&atto.codiceRedazionale=096G0680&elenco30giorni=false (Accessed July 2023)